Status:
COMPLETED
SAGIT for Classification of Patients With Acromegaly in Clinical Practice
Lead Sponsor:
Ipsen
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this pilot study is to test SAGIT (Signs and symptoms - Associated comorbidities - GH concentration level - IGF-1 - Tumour). SAGIT is a Clinician-Reported Outcomes (ClinROs) tool develo...
Eligibility Criteria
Inclusion
- Male or female aged 18 years-old or above
- Patient with diagnosis of acromegaly with the presence of pituitary adenoma, elevated IGF-1 and lack of serum GH suppression after oral glucose tolerance test (OGTT)
- Controlled/stable, active and treatment naïve patients.
- Patient with the cognitive and linguistic capacities to understand the information letter of the study
- Patient who signed informed consent
Exclusion
- History of non-compliance or inability to reliably receive treatment in the foreseeable future
- Gaps in treatment of greater than 1 month within the 12 months prior to study entry
Key Trial Info
Start Date :
February 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT02231593
Start Date
February 1 2013
End Date
May 1 2014
Last Update
March 31 2020
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
2
NW Pituitary Center and Neurological Surgery
Portland, Oregon, United States, 97239
3
Federal University of Minas Gerais
Belo Horizonte, Brazil, 31270-901
4
Private practice
Curitiba, Brazil, 80210070